Skip to main content
. Author manuscript; available in PMC: 2012 Oct 5.
Published in final edited form as: Oncogene. 2011 Sep 5;31(14):1804–1816. doi: 10.1038/onc.2011.361

Table 2.

Sensitivity of Melanoma cells to Nilotinib.

Cell Line WM278 WM239 A375 sbcl2 WM3248 435s/M14
Abl activity − − ++++ +++ ++++ ++++
Arg activity − ++ ++ ++ ++++ ++++
c-Kit − + − − − −
PDGFR-α + − − − − −
PDGFR-β − − − − − −
# of nilotinib targets 1 3 6 5 8 8
3H-Thymidine 41±8.4 36±2.07 26±2.4 39.5±1.5 12±0.38 32.7±.0.48

The level of c-Abl/Arg activities (Fig. 1) and presence of other nilotinib targets were tabulated, and +’s added together to create a “Score”. Outcome of tritiated thymidine incorporation assays using nilotinib (0.5μM) also are shown. An inverse correlation between the number of nilotinib targets and tritiated thymidine incorporation is shown in Figure 2d.